Prestige Biopharma IDC Obtains ISO 14001 and ISO 45001 Certifications

Following ISO 9001 Certification Earlier This Year, IDC Secures International Standards for Environmental and Occupational Health & Safety Management

Establishes Integrated Management Systems for Quality, Environment, and Occupational Health & Safety

Prestige Biopharma IDC, the innovative drug research and development subsidiary of Prestige Biopharma, has obtained international certifications in environmental management and occupational health and safety.

On September 17, Prestige Biopharma IDC announced that it had received ISO 14001 certification for its Environmental Management System and ISO 45001 certification for its Occupational Health and Safety Management System.

ISO 14001 is an international standard designed to help organizations systematically manage and continuously improve the environmental impacts associated with their operations. ISO 45001 is an international standard for identifying, assessing, and managing occupational health and safety risks in the workplace.

Prestige Biopharma IDC previously obtained ISO 9001 certification for its Quality Management System in January this year. With the addition of ISO 14001 and ISO 45001 certifications, the company has now established internationally recognized management systems covering quality, environmental management, and occupational health and safety.

Sang Seok Koh, CEO of Prestige Biopharma IDC, said, “Innovative drug development requires not only outstanding research capabilities but also a safe and sustainable research environment. Following our ISO 9001 certification, we have further expanded our certification framework with ISO 14001 and ISO 45001. Building on these standards in quality, environment, and occupational health and safety, we will continue to strengthen our R&D operations in line with international standards.”

Prestige Biopharma IDC is the innovative drug research and development (R&D) subsidiary of Prestige Biopharma Group. The company conducts research on antibody-based innovative therapeutics, next-generation treatment platforms, and diagnostic technologies.

Source: NewsPim (https://www.newspim.com/news/view/20260917000235)